Best Health Care Grants in Puerto Rico

The NIH Countermeasures Against Chemical Threats (CounterACT) initiative invites applications for basic research on chemical agents affecting the nervous system. This program aims to explore the toxicity mechanisms of chemical warfare agents, industrial chemicals, and pesticides. Researchers are encouraged to generate data that could reveal new therapeutic targets and manifestations of toxic exposures, contributing to public health safety against potential chemical threats.

The Animal and Veterinary Innovation Centers (U18) funding opportunity, led by the FDA, aims to foster collaborations with academic institutions to tackle critical veterinary health challenges. This includes addressing Highly Pathogenic Avian Influenza, promoting genomic advancements in agriculture, and developing veterinary solutions for minor species. Applications are invited to enhance animal health and public safety, with Letters of Intent due prior to the July 2024 deadline.

The National Institute of General Medical Sciences Predoctoral Basic Biomedical Sciences Research Training Program (T32) aims to cultivate a diverse array of skilled scientists to meet the biomedical research challenges of the nation. This program supports U.S. institutions in developing evidence-based biomedical graduate training and mentoring approaches. By integrating didactic, research, and career development components, it prepares trainees for impactful careers addressing critical health-related research needs.

The WaterSMART Applied Science Grants aim to enhance water management and supply reliability through innovative research and data utilization. By inviting qualified entities to apply for funding, the program focuses on improving hydrologic data access, forecasting capabilities, and modeling tools. This initiative aligns with federal priorities to optimize resources, ensuring water managers can effectively address future demands and adapt to climate challenges, thus fostering resilience in water operations across the nation.

The Cancer Research Education Grants Program (R25) aims to enhance research education in areas crucial to the NIH mission. This program supports innovative courses that develop skills in cancer research, covering topics such as prevention, diagnosis, and treatment. Grant applications are encouraged to be creative and state-of-the-art, addressing the needs of patients and their families. Key deadlines for applications span from January 2024 to September 2026, ensuring ongoing support for educational initiatives.

The NINDS Alzheimer’s Disease-Related Dementias (ADRD) K99/R00 program promotes diversity by supporting new independent investigators from underrepresented backgrounds in AD/ADRD research. This award facilitates a transition from mentored postdoctoral positions to independent faculty roles, providing essential NIH research support. Applicants must propose research that does not involve leading a clinical trial but may include participation in trials led by mentors. Key deadlines for applications span from October 2024 to June 2027.

The NINDS Faculty Development Award aims to enhance diversity in neuroscience research by supporting junior faculty from underrepresented backgrounds. This award provides essential research cost support, protected research time, and mentorship for individuals holding doctoral degrees within their first three years on a faculty tenure track. It specifically encourages research proposals that do not involve independent clinical trials, while allowing participation in trials led by mentors. Key application deadlines span from October 2024 to June 2027.

The B-INSPIRE program aims to foster behavioral interventions that enhance interest and preparedness for careers in biomedical research. It invites applications that propose innovative studies addressing motivation and persistence in research-oriented individuals. The initiative also encourages analyses of existing data to improve intervention methodologies. Successful projects should yield findings that support the implementation of diverse strategies across academic levels, ultimately enriching the biomedical research workforce.

The Health and Health Care Disparities grant aims to support innovative research that addresses the health challenges faced by individuals with disabilities, particularly in communities experiencing health disparities. Key application deadlines span from February 2024 to October 2026. This funding opportunity invites research proposals that explore the underlying factors affecting the health and well-being of these populations, promoting interventions that can lead to significant improvements in health equity.

The Cancer Health Equity Research Centers (CHERCs) initiative by the American Cancer Society aims to address health disparities by supporting research focused on social determinants affecting cancer care. This program encourages innovative projects that engage communities, enhance access, and improve outcomes across diverse populations. By fostering collaborations and promoting multidisciplinary approaches, CHERCs strive to create equitable cancer prevention and treatment solutions, ensuring that all individuals have fair opportunities for cancer care and survivorship.

The Institutional Research Grants (IRG) program by the American Cancer Society provides essential seed funding for newly independent investigators to launch cancer research projects. Aimed at junior faculty, these grants offer $120,000 annually for three years, supporting the development of preliminary results necessary for competing for larger national grants. Eligible applicants must be at US academic institutions and hold the rank of Associate or Full Professor, with a proven track record in research and mentorship.

The Exploratory Grant Award aims to enhance workforce diversity in basic cancer research by supporting junior and Early Stage Investigators from underrepresented groups in the biomedical and social sciences. This initiative provides essential funding to bridge the gap for researchers completing their training, ensuring they have the resources needed to develop larger grant applications. Applications are due by 5:00 PM local time of the applicant organization, emphasizing the importance of timely submissions.

The Ocean Technology and Interdisciplinary Coordination (OTIC) Program, funded by the National Science Foundation (NSF), supports innovative research and technology development in ocean science. This program welcomes unsolicited proposals for instrumentation that enhances the capabilities of the ocean research community. It also announces specific funding opportunities aimed at improving facilities and equipment at Biological Field Stations and Marine Laboratories, promoting interdisciplinary collaboration in oceanographic studies.

The National Institute on Aging (NIA) is set to release a Notice of Funding Opportunity (NOFO) aiming to stimulate research on Alzheimer's disease (AD) and related dementias (ADRD). This initiative focuses on validating novel drug targets and supports early-stage drug discovery efforts. The U01 activity code will be utilized, and while applications are not currently solicited, this notice allows potential applicants ample time to form collaborations and develop impactful projects in the field of AD/ADRD research.

The NIH is announcing a funding opportunity for competitive revisions of ongoing grants to tackle unforeseen public health crises. This Urgent Competitive Revision program aims to facilitate timely responses to emerging health challenges. Once the Notice of Funding Opportunity is published, eligible applications will be directly routed to the appropriate NIH awarding component. Only submissions in response to an Urgent Guide Notice published by an NIH Institute or Center will be accepted.

The FY26 Hearing Restoration Research Program (HRRP) Focused Research Award (FRA) aims to enhance drug discovery and therapeutic development for hearing restoration following military-related auditory injuries. The award supports preclinical and clinical studies aligned with HRRP focus areas. It features two funding levels, including a Partnering Principal Investigator option, and evaluates proposals based on research rationale, strategy, impact, and personnel. Notably, it excludes funding for clinical trials, tinnitus, and vestibular research.

The FY26 Breast Cancer Research Program's Transformative Breast Cancer Consortium Award fosters significant collaborations that aim to revolutionize care for individuals affected by breast cancer. This award supports a multidisciplinary consortium of leading scientists, clinicians, and advocates to tackle major challenges in breast cancer research. Proposals must address at least one of the program's overarching challenges and demonstrate a transformative impact that cannot be achieved by individual investigators alone.

The DoW Ovarian Cancer Pilot Award fosters innovative research that challenges existing paradigms in ovarian cancer. It aims to propel groundbreaking discoveries and advancements in the field. Notably, the award prioritizes originality over scientific merit alone, ensuring that innovative ideas are at the forefront. The application process includes a blinded pre-application screening to maintain confidentiality and integrity, encouraging fresh perspectives in ovarian cancer research.

The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award aims to support impactful research addressing critical needs in ovarian cancer and patient care. It requires a robust research plan with preliminary data and allows for studies across all research phases, excluding clinical trials. A unique Partnering Principal Investigator option encourages collaboration between two PIs to enhance research outcomes beyond individual efforts, promoting innovation in the field of ovarian cancer.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 3 supports transformative research aimed at significant advancements in breast cancer treatment. Applicants must address key challenges outlined by the program, ensuring their proposals demonstrate potential for impactful breakthroughs. This funding mechanism, which permits small-scale clinical trials, emphasizes collaboration by requiring research teams to include two breast cancer consumer advocates and allows for a single Principal Investigator or two partnering PIs.

The DoW Ovarian Cancer Clinical Trial Award, funded by the U.S. Army Medical Command, aims to accelerate the implementation of clinical trials that significantly impact ovarian cancer treatment. This award supports diverse trial designs, from early proof-of-concept studies to large-scale efficacy trials, evaluating innovative drugs, biologics, and technologies. By fostering research in this critical area, the program seeks to enhance patient outcomes and advance the understanding of ovarian cancer management.

The Ovarian Cancer Clinical Trial Academy (OCCTA) supports Early-Career Investigators (ECIs) in clinical trial research aimed at effective ovarian cancer treatments. It provides essential mentoring, networking, and skill development needed for executing clinical trials. The FY26 funding will specifically support translational research and early-phase trials, requiring preliminary data and a commitment of at least 25% effort from the ECI. Mentorship is vital, with a focus on experienced clinical trialists guiding ECIs.

The DoW Ovarian Cancer Academy Early-Career Investigator Award supports junior faculty in conducting innovative ovarian cancer research. Established in FY09, this unique virtual academy fosters mentorship, collaboration, and networking among Early-Career Investigators (ECIs) and their mentors. Participants engage in monthly webinars and annual workshops, enhancing their research skills while contributing to impactful studies in ovarian cancer. The program aims to cultivate a new generation of highly productive researchers in this critical field.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 supports innovative research with the potential for significant breakthroughs in breast cancer. Applications must address key BCRP challenges or justify exceptions, focusing on impactful solutions. This program mandates clinical trials and requires participation from breast cancer consumer advocates. The funding supports single or partnered Principal Investigators, ensuring comprehensive submission processes to avoid administrative withdrawal.

The FY26 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) aims to enhance clinical trials for ALS by developing and validating clinical outcomes and biomarkers. This funding opportunity encourages innovative projects that may focus on specific therapies, ALS subtypes, or digital health measures. Collaboration with the ALS community is essential to ensure that research is relevant and informed by lived experiences.

The FY26 Amyotrophic Lateral Sclerosis Research Program's Pilot Clinical Trial Award aims to accelerate clinical trials that can significantly impact ALS treatment and management. Focus areas include biomarker-driven interventions and improvements in clinical care. Trials must begin within 12 months of the award and incorporate community collaboration and a detailed regulatory strategy. This award emphasizes the importance of therapeutic interventions and a transition plan for advancing study outcomes beyond the funded work.

The FY26 DoW Pancreatic Cancer Research Program Focused Pilot Award aims to drive innovative and impactful research in pancreatic cancer, enhancing patient quality of life. This award encourages the development of preliminary data to support future clinical or real-world applications. While allowing for clinical research studies, it does not permit clinical trials or preclinical animal studies, ensuring a strong patient-centered approach in its research focus.